Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AHDC1 is a nuclear protein distinguished by its two AT-hook DNA-binding motifs, which facilitate its association with AT-rich DNA regions[1][4]. The AT-hook domain allows binding to the minor groove of DNA, altering chromatin architecture and influencing transcription[3][6]. AHDC1 participates in the regulation of gene expression during development, particularly in patterning the epidermis and epithelial morphogenesis[7]. Mutations—especially truncating or missense variants—lead to Xia-Gibbs syndrome, characterized by developmental delay, intellectual disability, hypotonia, sleep disturbances, limited speech, and distinct dysmorphic features[1][4][7]. AHDC1 is also reported to influence tumor progression in cancer contexts via regulatory RNA networks[4]. There is so far no evidence of direct drug interactions, and it is not considered a conventional therapeutic target, but its mutation status serves as a genetic biomarker for certain syndromic diseases[1][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AT-hook DNA binding motif containing 1 (AHDC1).